Antigenic peptides derived from telomerase
CA 2336743 C · Owner: Saeboe-Larsen, Stein · Inventors: Saeboe-Larsen, Stein; Eriksen, Jon Amund; Moller, Mona
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to proteins or peptides which elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognising and destroying tumour cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 30, 1999 and granted October 11, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 30, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 30, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.